BLS — BLS Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- AU$255.28m
- AU$250.42m
- AU$74.23m
Brief: Bioxyne And CY Biopharma Forge Strategic Alliance To Develop New Psilocybin Therapies In Austrasia
Brief: Bioxyne Says Received Firm Commitments To Raise A$1.45 Million At A$0.01 Per Share
Brief: Bioxyne Posts HY Loss Attributable A$12.3 Million
Brief: Bioxyne Says Awarded Gmp Manufacturing License For Medical Cannabis
Australia's Bioxyne jumps on unit securing manufacturing license for medical cannabis
Brief: Bioxyne Qtrly Group Revenue About A$2.1 MLN, Up 75%
Brief: Bioxyne Updates On Australian Medicinal Cannabis Business
Brief: Bioxyne Signs Joint Venture With Canxchange
Brief: Bioxyne Says Extended Amazon Footprint Into U.S. And Japan
Brief: Bioxyne Executes Sale And Purchase Agreement To Acquire Breathe Life Sciences
Australia's Bioxyne hits 2-week low on drop in HY23 sales revenue
Brief: Bioxyne Says Enters Into Binding Term Sheet To Acquire Breathe Life Sciences
Australia's Bioxyne rises on acquisition of health and wellness firm
Brief: Bioxyne Records Qtrly Sales Revenue A$0.5 Million
Bioxyne hits highest since Jan on deal with Singapore PE group
Brief: Bioxyne Joins Asian Partner & Sells 49% Of Direct Selling Business
Brief: Bioxyne Says March Revenues 147% Up Quarter On Quarter
Australia Stock Exchange release from BIOXYNE : Change of Director's Interest Notice
Australia Stock Exchange release from BIOXYNE : Appendix 4D and Interim Report